Os30

Cat. No.:	HY-155358
CAS No.:	2998928-68-8
Molecular Formula:	$C_{27}H_{33}N_7O_2S$
Molecular Weight:	519.66
Target:	EGFR; Apoptosis
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (96.22 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9243 mL	9.6217 mL	19.2434 mL
	5 mM	0.3849 mL	1.9243 mL	3.8487 mL
	10 mM	0.1924 mL	0.9622 mL	1.9243 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (4.81 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Os30, a potent fourth-generation EGFR inhibitor, is a potent EGFRC797S-TK inhibitor with IC_{50} values of 18 nM and 113 nM for EGFRDel19/T790M/C797S TK and EGFRL858R/T790M/C797S TK, respectively. Os30 can suppress EGFR phosphorylation, arrest at G1 phase and induce the apoptosis of KC-0116 (BaF3-EGFRDel19/T790M/C797S) cells. Os30 shows potent antitumor efficacy on non-small cell lung cancer (NSCLC) with EGFmRC797S mutation[1].

REFERENCES

[1]. Xiao-Xiao Xi, et al. Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors. Eur J Med Chem. 2023 Dec 5:261:115865.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA